Quick Answer
Cytek Biosciences, Inc. reported Total Revenue of $201.49 million for the year ending 2025.
- Cytek Biosciences, Inc. showed an increase of +0.5% in Total Revenue from 2024 to 2025.
- This data is from Cytek Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $19.14 million | Q3 2020: $25.10 million | Q1 2021: $24.27 million | Q2 2021: $30.41 million | Q3 2021: $34.38 million | Q1 2022: $35.06 million | Q2 2022: $40.16 million | Q3 2022: $40.48 million | Q1 2023: $37.09 million | Q2 2023: $49.69 million | Q3 2023: $48.00 million | Q1 2024: $44.86 million | Q2 2024: $46.62 million | Q3 2024: $51.50 million | Q1 2025: $41.46 million | Q2 2025: $45.60 million | Q3 2025: $52.29 million.
- Over the full 6 years of available data (2020 to 2025), Cytek Biosciences, Inc.'s Total Revenue has grown by 117.0%.
- Historical annual values: Fiscal year 2025: $201.49 million | Fiscal year 2024: $200.45 million | Fiscal year 2023: $193.02 million | Fiscal year 2022: $164.04 million | Fiscal year 2021: $127.95 million | Fiscal year 2020: $92.84 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: